Big pharma, Biotech, Partnering, Pharma

Astrazeneca and Mitsubishi signs a pharma alliance for kidney failure

Posted on 21 August 2014

Tags: , , ,

Astrazeneca and Mitsubishi  have signed a pharma alliance for early-stage three-year research collaboration to develop small molecule candidates from their respective portfolios that have been identified as treatments for the disease which involves kidney failure due to diabetes.

Diabetic nephropathy occurs in as many as 50% of patients who have diabetes for 20 years or more.

The research will be performed at MTPC’s facilities in Japan and at AstraZeneca’s cardiovascular and metabolic disease innovative medicines unit in Molndal, Sweden.

There is no financial commitment for the research involved and each firm will contribute equal resources at their own cost.

For further deal information visit Current Agreements (subscription required)

Related

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply